Peptides Codex
ENFR
← Home
Incretin mimetic (GLP-1 receptor agonist)

Albiglutide

Albiglutide is a GLP-1 receptor agonist created by genetically fusing two modified GLP-1 sequences to human serum albumin, giving it a long half-life suited to once-weekly dosing. Approved as Tanzeum and Eperzan in 2014, it was later withdrawn from the market for commercial reasons and is now a historical case study.

By The Peptides Codex Editorial TeamReviewed July 10, 2026
Length
n/a
Class
Incretin mimetic (GLP-1 receptor agonist)
Function
Albumin-fused GLP-1 receptor agonist engineered for a long half-life
Context
Previously approved (EU and United States); withdrawn from the market for commercial reasons

A GLP-1 agonist fused to albumin — half-life extension by protein engineering rather than a fatty-acid chain.

Also known as: Tanzeum · Eperzan

Part of the Metabolic & GLP-1 peptides cluster

Overview

Albiglutide is a GLP-1 receptor agonist created by genetically fusing two modified GLP-1 sequences to human serum albumin, giving it a long half-life suited to once-weekly dosing. Approved as Tanzeum and Eperzan in 2014, it was later withdrawn from the market for commercial reasons and is now a historical case study.

Source & context

Biological / chemical source: Recombinant fusion of two GLP-1 dimers to human serum albumin

Primary research or clinical context: Previously approved (EU and United States); withdrawn from the market for commercial reasons

Half-life by albumin fusion

Rather than attaching a fatty-acid side chain like semaglutide, albiglutide fuses its GLP-1 sequence directly to albumin — the most abundant, long-lived protein in blood. The GLP-1 portion is also modified for DPP-4 resistance. This makes it a distinct illustration of the fusion-protein approach to extending peptide half-life.

Approval and withdrawal

Albiglutide was an approved prescription medicine before its manufacturer withdrew it from the global market for economic reasons, with supplies depleted by 2018. It is described here as a regulated, now-discontinued product for educational context only, not as an available treatment.

FAQ about Albiglutide

What is Albiglutide?+

Albiglutide is a GLP-1 receptor agonist created by genetically fusing two modified GLP-1 sequences to human serum albumin, giving it a long half-life suited to once-weekly dosing. Approved as Tanzeum and Eperzan in 2014, it was later withdrawn from the market for commercial reasons and is now a historical case study.

Is Albiglutide an approved medicine?+

Albiglutide: Previously approved (EU and United States); withdrawn from the market for commercial reasons. Always follow licensed medical guidance for approved products.

What is the typical length of Albiglutide?+

Albiglutide is not a classic amino-acid chain peptide in the same sense; see the profile for classification details.

Related peptides

Motilin
Gut hormone
Motilin is a 22-amino-acid gut hormone secreted by endocrine cells of the small intestine. It coordinates the migrating motor complex, the wave of contractions that clears the digestive tract between meals, earning it the nickname the housekeeper of the gut.
Obestatin
Gut hormone
Obestatin is a 23-amino-acid peptide cleaved from the same preproghrelin precursor that produces ghrelin. It was originally proposed to oppose ghrelin's appetite-stimulating effects, though its physiology and receptor remain actively debated in the research literature.
Lixisenatide
Incretin mimetic (GLP-1 receptor agonist)
Lixisenatide is a synthetic GLP-1 receptor agonist built on the exendin-4 scaffold rather than on human GLP-1. Marketed as Lyxumia and Adlyxin, it is an approved prescription medicine in the EU and United States and a useful case study in how venom-derived peptides are adapted into once-daily therapeutics.
Efpeglenatide
Incretin mimetic (GLP-1 receptor agonist)
Efpeglenatide is a long-acting GLP-1 receptor agonist built from an exendin-based peptide conjugated to an antibody Fc fragment for extended duration. It has been evaluated in large clinical programs, including the AMPLITUDE-O cardiovascular-outcomes trial, and remains investigational — it is not authorized by Health Canada.

References & further reading

  1. 1.Wikipedia — Albiglutide
  2. 2.PubChem — compound summary for Albiglutide (CID 122173812)
Disclaimer: Educational content only. Not medical advice. Not instructions for human use. Research peptides and unapproved products may be restricted or illegal to market for human consumption in your jurisdiction. Consult qualified professionals and applicable law.
You might also like: All peptides · Atlas · Research · Tools
Cite this: Peptides Codex — Albiglutide educational profile.
Tip: Use browser print (Ctrl/Cmd + P) for a clean PDF of this page.